Efficacy and Safety of Ruxolitinib in Primary Myelofibrosis Patients with Abdominal Thrombotic Complications: A Case Series

BACKGROUND. Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm of hematopoietic stem cells characterized by excessive production of proinflammatory profibrogenic cytokines providing runaway proliferation and accumulation of mature blood cells along with developing reticulin/collagen bone marrow fibrosis. Long-term survival rates shown by PMF patients are considerably lower than population-based survival rates, not least because of life-threatening portal vein thrombotic complications and Budd-Chiari syndrome. Ruxolitinib is the first pathogenic targeted drug blocking the JAK2 kinase activity in PMF. This drug persistently reduces the spleen size and the intensity of constitutional symptoms. However, for this category of patients the role of ruxolitinib in thrombosis risk reduction has until now remained underresearched.

AIM. To assess the efficacy and safety of ruxolitinib in PMF patients with abdominal thrombosis.

MATERIALS & METHODS. Case reports of 4 PMF patients treated with ruxolitinib. At disease onset, portal vein thromboses were detected, that required liver transplantation in 2 out of 4 cases.

RESULTS. The present paper reports success with ruxolitinib in 4 PMF patients. Ruxolitinib dose modification as well as side effect control, when administered concurrently with other immunosuppressive drugs, facilitates health status stabilization, spleen reduction, and improvement of constitutional symptoms.

CONCLUSION. Ruxolitinib therapy in PMF patients with portal and hepatic vein thrombosis promotes better quality of life and reduces the risk of repeated thrombotic complications. After liver transplantation, PMF patients need further optimization of dosing schedule of chemotherapy and immunosuppressive therapy with most careful monitoring of adverse events.

• Yu.P. Martinova Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040 https://orcid.org/0009-0006-2045-7026 (unauthenticated)
• E.V. Borovitskaya Pyatigorsk Interdistrict Oncology Dispensary, 31 Kalinina pr-t, Pyatigorsk, Russian Federation, 357502 ; Zhenskaya liniya, Center for Effective Gynecology, 52 korp. 1 Nezhnova ul., Pyatigorsk, Russian Federation, 357502
• S.S. Lebedeva Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040 ; Kuban State Medical University, 4 Mitrofana Sedina ul., Krasnodar, Russian Federation, 350063 https://orcid.org/0009-0000-1594-6219 (unauthenticated)
• E.R. Efimova Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040
• O.E. Filippova Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040
• K.M. Chernysh Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040
• A.P. Smaglyuk Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040
• L.I. Napso Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040
• N.V. Novospasskaya Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040
• L.V. Kucheryavykh Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040
• Tamara Vangelevna Chitanava Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040 https://orcid.org/0000-0002-9390-9154 (unauthenticated)

1. Verstovsek S, Mesa RA, Livingston RA, et al. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023;16(1):82. doi: 10.1186/s13045-023-01471-z. DOI: https://doi.org/10.1186/s13045-023-01471-z
2. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801–21. doi: 10.1002/ajh.26857. DOI: https://doi.org/10.1002/ajh.26857
3. Chung RT, Iafrate AJ, Amrein PC, et al. Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. N Engl J Med. 2006;354(20):2166–75. doi: 10.1056/NEJMcpc069006. DOI: https://doi.org/10.1056/NEJMcpc069006
4. Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005:409–15. doi: 10.1182/asheducation-2005.1.409. DOI: https://doi.org/10.1182/asheducation-2005.1.409
5. Martinelli I. Unusual forms of venous thrombosis and thrombophilia. Pathophysiol Haemost Thromb. 2002;32(5–6):343–5. doi: 10.1159/000073595. DOI: https://doi.org/10.1159/000073595
6. Меликян А.Л., Суборцева И.Н., Барышникова Д.В. и др. Тромботические и геморрагические осложнения у больных первичным миелофиброзом. Данные регистра Ph-негативных миелопролиферативных заболеваний. Гематология и трансфузиология. 2020;65(S1):38. [Melikyan A.L., Subortseva I.N., Baryshnikova D.V., et al. Thrombotic and hemorrhagic complications in patients with primary myelofibrosis. Data from the Registry of Ph-Negative Myeloproliferative Neoplasms. Gematologiya i transfuziologiya. 2020;65(S1):38. (In Russ)]
7. Frey HR, Suter B. Portal vein and hepatic vein thrombosis in occult myeloproliferative syndrome. Progression of thrombosis under heparin therapy. Schweiz Med Wochenschr. 1996;126(34):1437–41.
8. Arana YiC, Tam CS, Verstovsek S. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol. 2015;11(5):719–33. doi: 10.2217/fon.14.272. DOI: https://doi.org/10.2217/fon.14.272
9. Samuelson BT, Vesely SK, Chai-Adisaksopha C, et al. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis. 2016;27(6):648–52. doi: 10.1097/MBC.0000000000000446. DOI: https://doi.org/10.1097/MBC.0000000000000446
10. Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. J Hepatol. 2006;44(3):520–8. doi: 10.1016/j.jhep.2005.12.002. DOI: https://doi.org/10.1016/j.jhep.2005.12.002
11. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843–4. doi: 10.1182/blood-2013-10-531103. DOI: https://doi.org/10.1182/blood-2013-10-531103
12. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) consensus report. Blood. 2013;122(8):1395–8. doi: 10.1182/blood-2013-03-488098. DOI: https://doi.org/10.1182/blood-2013-03-488098
13. Tefferi A, Barosi G, Passamonti F, et al. Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024;144(17):1813–20. doi: 10.1182/blood.2024025802. DOI: https://doi.org/10.1182/blood.2024025802
14. Fisher LR, Henley KS, Lucey MR. Acute cellular rejection after liver transplantation: variability, morbidity, and mortality. Liver Transpl Surg. 1995;1(1):10–5. doi: 10.1002/lt.500010104. DOI: https://doi.org/10.1002/lt.500010104
15. Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl. 2004;10(7):859–67. doi: 10.1002/lt.20157. DOI: https://doi.org/10.1002/lt.20157
16. Escamilla Gómez V, García-Gutiérrez V, López Corral L, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant. 2020;55(3):641–8. doi: 10.1038/s41409-019-0731-x. DOI: https://doi.org/10.1038/s41409-019-0731-x
17. Dold L, Lutz P, Heine A, et al. Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation. Clin Case Rep. 2021;9(9):e04782. doi: 10.1002/ccr3.4782. DOI: https://doi.org/10.1002/ccr3.4782
18. Pieri L, Paoli C, Arena U, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol. 2017;92(2):187–95. doi: 10.1002/ajh.24614. DOI: https://doi.org/10.1002/ajh.24614